Regulatory Submission in Europe in Absence of Reference product [Regulatives / Guidelines]

posted by dshah  – India/United Kingdom, 2021-03-23 09:51 (459 d 17:59 ago) – Posting: # 22290
Views: 6,491

Hi Abhay Patil!
In absence of Innovator product in EU and UK market for FDC, you may have to do BE against individual drug substance innovator product. Please see Guideline on clinical development of fixed combination medicinal products.
Regards,
Dshah

Complete thread:

UA Flag
Activity
 Admin contact
22,167 posts in 4,645 threads, 1,572 registered users;
online 5 (0 registered, 5 guests [including 5 identified bots]).
Forum time: Sunday 04:50 CEST (Europe/Vienna)

The person interested in success has to learn
to view failure as a healthy, inevitable part
of the process of getting to the top.    Joyce Brothers

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5